Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 6/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.49 |
| ▸ | CDK9 | P50750 | 6/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | CDK7 | P50613 | 3/20 | 0.47 |
| ▸ | CCNH | P51946 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971567 | 0.90 | JAK3 (0.47) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4971269 | 0.89 | JAK3 (0.48) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4975452 | 0.88 | JAK1 (0.49) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4975028 | 0.87 | SYK (0.52) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4981957 | 0.87 | CDK2 (0.46) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL1115767 | 0.85 | TNNI3K (0.44) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL1115641 | 0.84 | AURKA (0.35) | JAK3CDK2CDK1CDK9CDK5 | |
| SCHEMBL5010524 | 0.84 | JAK3 (0.45) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4972184 | 0.82 | JAK3 (0.49) | JAK1JAK3CDK2CCNT1CDK1 | |
| SCHEMBL4972193 | 0.82 | JAK3 (0.49) | JAK1JAK3CDK2CCNT1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | claimed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| EP-1991532-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9481654-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-8962643-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-1991532-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007098507-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203162-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | JAK1 2/4885JAK3 1/4885CDK2 986/4885 |
| US-20150158824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885CDK2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.